Navigation Links
Hospira Announces Executive Changes
Date:3/1/2013

LAKE FOREST, Ill., March 1, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Royce R. Bedward has been appointed corporate vice president, general counsel and secretary, effective immediately. In his new role, Mr. Bedward will oversee the company's legal department, including litigation, benefits, labor and employment, intellectual property, governance, securities and transactional matters. He will report to Brian Smith , who has served as Hospira's senior vice president and general counsel since its spin-off in 2004, and now assumes the newly created role of chief legal officer, including responsibility for government affairs. Both Mr. Smith and Mr. Bedward will serve as members of the company's senior leadership team, led by F. Michael Ball , chief executive officer.

(Photo: http://photos.prnewswire.com/prnh/20130301/CG69263)

"Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira," said Mr. Ball. "We look forward to Royce's many additional contributions, while thanking Brian for his continued service and counsel. Working together, I'm confident that their strong leadership abilities will help position Hospira for a stronger future of sustainable, long-term growth and drive greater value for our stakeholders."

Mr. Bedward, 47, is one of the founding members of Hospira's legal leadership team, joining the company at its inception as its vice president of litigation, and assuming roles of increasing responsibility, most recently holding the position of deputy general counsel and secretary.  Prior to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... the risk of cancer returning,after surgery for ... April 12, 2007 /PRNewswire/ -- Investigators,will begin ... placebo in a major North American clinical ... Kit-positive,gastrointestinal stromal tumors treated with Gleevec following,surgery ...
... and NUTLEY, N.J., April 12, 2007,/PRNewswire-FirstCall/ -- ... trial program ever undertaken in the renal,anemia ... the,investigational anemia therapy MIRCERA(TM) for the treatment ... (CKD) in,patients on dialysis and not on ...
Cached Medicine Technology:Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 2Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 3Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 4Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 6Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 7Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 2Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 3Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 4
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently ... molecule in metastatic breast cancer reduces both the growth ... BRI scientists have found in models of the disease ... - 80 percent and can keep the tumor from ... five-year grant comes from the National Cancer Institute of ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... new studies show higher joint replacement complication rates, longer ... The prevalence of obesity is rising at ... with this life-altering condition may be putting their long-term ... at the 2009 Annual Meeting of the American ...
... Orthopaedic surgeon John J. Callaghan, MD was elected to ... Orthopaedic Surgeons ( http://www.aaos.org/ )(AAOS) at the organization,s 2009 ... Academy as First Vice-President.Having to wear a cast as a ... go into the field of orthopaedic surgery. "Breaking my ...
... that boys and girls can return to high-level sports ... high school athletes receiving anterior cruciate ligament ( ACL ... return to their sport at the same level, and ... rate. A new study presented today at the 2009 ...
... for psychiatric services following an emergency room visit are ... call for help, compared to about 20 percent of ... percent of all calls to mental health clinics in ... two weeks, according to a new University of Pennsylvania ...
... February 2009 Molecular Oncology (MOLONC) ... of the Federation of European Biochemical Societies (FEBS), ... for inclusion in the Science Citation Index Expanded ... , MOLONC (published 6 times a year from ...
... 8x BD writer drive, Vinpower Digital is able to offer the ... , ... Los Angeles, CA (PRWEB) February 25, 2009 ... Disc duplicator lines offering true 8X BD-R duplication speed. Using ...
Cached Medicine News:Health News:Obesity: A Musculoskeletal Nightmare 2Health News:Obesity: A Musculoskeletal Nightmare 3Health News:Obesity: A Musculoskeletal Nightmare 4Health News:John J. Callaghan, MD Elected Academy First Vice President 2Health News:John J. Callaghan, MD Elected Academy First Vice President 3Health News:Getting on the Ball, Post-ACL Surgery 2Health News:Getting on the Ball, Post-ACL Surgery 3Health News:For psychiatric services, wait for the beep 2Health News:For psychiatric services, wait for the beep 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:Vinpower Digital Increases Blu-ray Disc Duplication Speed to 8X for Both Their Manual Tower and Autoloader Series Duplicators 2Health News:Vinpower Digital Increases Blu-ray Disc Duplication Speed to 8X for Both Their Manual Tower and Autoloader Series Duplicators 3
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Assay for Determination of Initial Thrombin Formation...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit PiCT LMWH Calibrators...
Medicine Products: